How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/laron-type-isolated-somatotropin-defect.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Laron-type isolated somatotropin defect — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Laron-type isolated somatotropin defect (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Laron-type isolated somatotropin defect, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Target	First approval
MECASERMIN RINFABATE	MECASERMIN RINFABATE	Insmed		2005-01-01
Increlex	MECASERMIN	Ipsen Inc	Insulin-like growth factor 1 receptor	2005-01-01
Increlex	Increlex	Children's Hospital Medical Center, Cincinnati	Insulin receptor, Insulin-like growth factor 1 receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Children's Hospital Medical Center, Cincinnati · 1 drug in Laron-type isolated somatotropin defect
Insmed · 1 drug in Laron-type isolated somatotropin defect
Ipsen Inc · 1 drug in Laron-type isolated somatotropin defect

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Laron-type isolated somatotropin defect:

Cite this brief

Drug Landscape (2026). Laron-type isolated somatotropin defect — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/laron-type-isolated-somatotropin-defect. Accessed 2026-06-10.

Laron-type isolated somatotropin defect full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing